Hereditary complement factor I deficiency by VYSE, T.J. et al.
QJMed, 1994; 87:385-401
Original papers
Hereditary complement factor I deficiency
T.J. VYSE, P.J. SPATH1, K.A. DAVIES, B.J. MORLEY, P. PHILIPPE2,
P. ATHANASSIOU, C M . GILES and M.J. WALPORT
From the Rheumatology Unit, RPMS, Hammersmith Hospital, London, UK,
^ZLB, Central Laboratory, Blood Transfusion Service, SRC, Berne, Switzerland,
and2Regional Hospital Delemont, Detemont, Switzerland
Received 17 March 1994; Accepted 13 April 1994
QJM
Summary
We describe four cases (from three families) of
hereditary factor I deficiency, bringing the total
number of cases now reported to 23. In one family
there are two affected siblings: one has suffered
recurrent pyogenic infections; the other is asympto-
matic. In the second family, the patient had recur-
rent pyogenic infections and a self-limiting vasculitic
illness; in the third family, the patient suffered recur-
rent pyogenic and neisserial infections. All four
patients had markedly reduced concentrations of C3
in the serum (family 1 propositus: 28%; family 1
asymptomatic sibling: 15%; family 2: 3 1 % ; and
family 3: 31 % normal human serum) which was in
the form of C3b. Low lgG2 levels may occur in
primary C3 deficiency, and a reduction in lgG2
concentration to 1.14 g/l (normal: 1.30-5.90 g/l)
was found in the patient from family 2. Using radio-
ligand binding assays, we demonstrated increased
binding of C3b to erythrocytes in a patient with
factor I deficiency. This C3b could not be cleaved
by autologous serum but could be cleaved by normal
serum or purified factor I. We review and compare
the published cases of C3, factor H and factor I
deficiency.
Introduction
Complement factor I (Fl) is a serine esterase that acts
to control the amplification loop of the alternative
pathway of the complement cascade. Hereditary
deficiency of Fl is a rare autosomal recessive condi-
tion. In the absence of Fl, the amplification loop of
the alternative pathway is activated in an uncon-
trolled fashion, so that there is consumptive loss of
complement C3.1- t Secondary depletion of C3 is
also caused by genetic deficiency of complement
component factor H (FH), which is a cofactor for Fl.
The study of these hereditary deficiencies is important
because of the evidence that they provide in relation
to the roles of the complement system in vivo.
Furthermore, it was the investigation of the physi-
ology of the complement system in the first case of
Fl deficiency1"* that generated much of the early
evidence for the existence of the amplification loop
of the alternative pathway.5
The clinical effects of C3, Fl and FH deficiency
are similar: a propensity to suffer recurrent pyogenic
infections and an increased incidence of glomerulo-
nephritis and SLE-like illness. The clinical con-
sequences of C3 deficiency reflect the role played
by the complement system in the opsonization of
pathogens and the clearance of immune complexes.6
Although there are subtle differences in the effects
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of these three conditions on the complement system,
the predominant influence on the clinical outcome
in all three states is that of C3 deficiency.
To date, 19 patients with Fl deficiency have been
reported.7"19 We report an additional four patients
from three families. In one family, there were two
homozygously affected siblings; one of whom suf-
fered recurrent pyogenic infections, the other being
healthy. In the other two families there were single,
homozygous, symptomatic individuals. We review
the clinical features of Fl deficiency, and then
compare them with the clinical consequences of FH
and C3 deficiencies. The clinical features of all the
reported cases of these hereditary deficiencies are
tabulated (see Table 1) and their pathogenesis and
treatment are briefly discussed.
Patients
Family 1
A 14-year-old boy presented with a history of recur-
rent pyogenic infections that began at the age of 18
months. At this time he developed a septic arthritis
of the left shoulder from which Staph. epidermidis
was cultured. At the age of 5 years he suffered
orbital cellulitis, and over the next 5 years he had
recurrent episodes of sinusitis. When 8 years old, an
abscess on the side of his neck was drained. At the
age of 13 he had a single episode of meningococcal
meningitis. He has subsequently had a number of
minor respiratory tract infections. Physical examina-
tion was unremarkable. There was no family history
of immunodeficiency or autoimmune disease, and
no consanguinity, although both parents originate
from western Scotland. He has one sibling, a sister
who is 5 years older, who has neither suffered from
any major episodes of infection with pyogenic organ-
isms, nor had recurrent sinusitis or otitis media.
Investigation of both siblings revealed a normal
full blood count and basic biochemistry profile. The
immunoglobulin concentrations of both siblings were
within the normal ranges: the affected male's values
were: IgG 10.5 g/l (normal: 7.2-16.2); IgA 1.3 g/1
(0.8-3.9); IgM 2.3 g/l (0.5-3.5); his sister's values
were: IgG 9.5 g/l (7.2-16.2); IgA 1.1 g/l (0.8-3.9);
IgM 1.5 g/l (0.5-3.5). The IgG subtype concentrations
gave no evidence of selective isotype deficiency: the
affected male's concentrations were: IgG, 9.05 g/l
(3.2-10.2); lgG2 2.97 g/l (1.2-6.6); lgG3 1.25 g/l
(0.2-1.9); lgG4 0.20 g/l (0.10-1.3); the IgG subtype
levels of the asymptomatic sister were as follows:
IgG, 10.05 g/l (3.2-10.2); IgG, 2.73 g/l (1.2-6.6);
lgG3 1.55 g/l (0.2-1.9); lgG4 0.20 g/l (0.10-1.3).
Antinuclear antibodies (ANA) (measured by indirect
immunofluorescence on Hep-2 cells) and rheumatoid
factor (measured by Latex agglutination) were not
detected. His complement system was investigated
together with that of all four family members (see
Table 2). The results demonstrate the diagnosis of Fl
deficiency in the patient and in his asymptomatic
elder sister: Fl was undetectable in both siblings, as
was factor B (FB); there was no detectable alternate
pathway activity (APH50); and both FH and proper-
din levels were reduced. Both parents had approxi-
mately half the normal concentration of circulating Fl.
The patient is being treated with prophylactic
phenoxymethylpenicillin, 250 mg bd. He was vac-
cinated with Pneumovax and mounted a significant
lgG2 response: pre-immunization 1:16; post-
immunization 1 :110; control 1 :160 (measured by
Dr Kumaratne, Immunology Dept, Dudley Road
Hospital, Birmingham). He is now aged 19 years
and has had no further significant infective episodes.
His sister, who is 24 years old, also remains well.
Family 2
The affected male in this pedigree has suffered from
recurrent otitis media since infancy. He had one
episode of idiopathic keratitis when aged 5 years.
Because of recurrent sinusitis, surgery to the nasal
septum was performed at age 14 and it was noted
that he was allergic to both penicillin and sulphon-
amides. When he was 16 years old, he suffered four
bouts of left-sided bronchopneumonia together with
sinusitis. Str. pneumoniae and Staph. aureus were
cultured from the sputum. The following year a
bronchogram was performed, no lesion was demon-
strated, but an episode of bronchopneumonia was
precipitated. When aged 20, a sixth episode of
bronchopneumonia occurred. Five years later, he
had a self-limiting illness characterized by hepatitis,
pneumonitis, myositis, possible meningitis, and pur-
pura, with histological evidence of a microangi-
opathic vasculitis on skin biopsy. During the next
ten years, he had five additional episodes of broncho-
pneumonia.
At the age of 36 he was fully investigated, and
the diagnosis of Fl deficiency was established. He
had a normal full blood count and biochemistry. His
ANA and rheumatoid factor were negative. The
concentrations of immunoglobulin isotypes were
within the normal ranges, however, analysis of IgG
subtypes: IgG, 11.49 g/l (3.55-11.25); lgG2 1.14 g/l
(1.30-5.90); lgG3 0.44 g/l (0.15-1.05); lgG4 0.54 g/l
(0.10-1.10), indicated that the lgG2 concentration
was diminished. Analysis of the complement system
confirmed the diagnosis of Fl deficiency (see Table 3).
Additional family members were also studied (see
Figure 1) indicating the inheritance of the trait
throughout the family. This family is Swiss/German
in origin, there is no known consanguinity. The
Table 1a Hereditary Factor I deficiency: twenty-three patients from nineteen families (separated by lines)
Patient Age Sex Nationality Consanguinity Age of
(years) Race onset
Infections Other complications
Klinefelter's
syndrome XXY
Urticaria
Notes
Became C3 Coombs negative
for 14 days and had
undetectable C3b and 17 days
after infusion of normal plasma
C3 and C5 levels raised for 12
days but FB levels maintained for
only 3 days after infusion of
purified Fl
Reference
(1)
(2)
(3)
(4)
1 25 M USA 1 year Haemorrhagic measles
Recurrent otitis media
Recurrent sinusitis
Inguinal abscess
Auricular abscess: C. diphtheriae
Septicaemia x 2 : Str. pyogenes
N. meningitidis
Pneumonia: H. influenzae
2 11 F English no
Caucasoid
4 months Meningitis x 4:
Str. pneumoniae x 1
N. meningitidis x 2
Otitis media
(7)
oI
I"
8-
1'
5
? F USA ?
4 ?
Meningitis x 3 H. influenzae b
N. meningitidis
3 months Pneumonia x 1
(8)
5 3 M Germany 6 months Gastroenteritis
Recurrent otitis media
Septicaemia
UTI x 3
IgM rheumatoid Abnormal FH mobility
factor positive (by immunoelectrophoresis)
probably due to its binding to C3b
ANA negative Infusion of plasma (FFP):
C5 and FH elevated above pre-
infusion levels for up to 1 month
FB increased for 6 h only
No complications after 22 infusions
of FFP
(9)
28 M Canada
Caucasian
No Infancy Recurrent otitis, bronchitis, and
mastoiditis
Pneumonia x 4 Serum sickness-like
Pleural empyema: Str. pneumoniae illness following the
Bronchiectasis administration of
Meningitis penicillin
5 of 10 siblings died in infancy
3 from sepsis, ?FI status
IgM rheumatoid factor (1 :1280)
ANA negative
(10)
00
Table la
Patient
7
(continued)
Age Sex
(years)
19 F
Nationality
Race
Denmark
Caucasoid
Consanguinity
No
Age of
onset
19 years
Infections
Otitis media
Meningitis: N. meningitidis CpB
Herpes zoster
Other complications Notes Reference
(11)
(12)
8 15/12 F USA 3 weeks Septicaemia: Str. pneumoniae
Pneumonia: Str. pneumoniae
Otitis media
?Osteomyelitis
low IgA (0.36 g/1) Infusion of Fl:
C3 and FB increased for 4 days
FH and CH50 increased for 14 days
Fl remained undetectable
(13)
00
00
9 9 ? France
?
? Recurrent bronchitis, otitis media
and mastoiditis
Reduced erythrocyte CR1
Normal range 300-1320
(14)
10 ? ? France ?
11 ? France
9 years Arthritis: septic ?agent
11 years Arthritis: N. meningitidis
Reduced erythrocyte CR1
Normal range 300-1320
patients: 10-115; 11-182
Defective CRT- and CR3-dependent
phagocytosis
(14)
12
13
14
15
37
37
27
?
M
F
M
M
?
Caucasoid
Caucasoid
Tunisian
No
No
No
Childhood Recurrent otitis, sinusitis
Pneumonia x 8
Meningitis x 5:
N. meningitidis (GpB x 1, W135
x l )
Septicaemia with DIC x 2
37 years Fatal systemic vasculitis: cutaneous
leucocytoclastic lesions
Haematuria and proteinuria
Deep venous thrombosis
Perivenous encephalomyelitis
(diagnosed at post-mortem)
Childhood Recurrent otitis media and
cutaneous abscesses
Vasculitic illness
followed the
administration of
penicillin for
pharyngitis
Cryoglobulinaemia
ANA not reported
Asymptomatic
Treatment with FFP: (15)
C3 increase 16 days
Native FB increase 4 days
Fall in C4 and rise in C4d duration
- 2 days
Fl half-life estimated 29 h
Anaphylaxis with 8th and 9th FFP
infusions
Very low, but detectable levels of (15)
Fl, C3d and C4d also detectable
(?from blood transfusion)
(16)
In
20 France Yes
?Caucasian (second
cousins)
17 months Recurrent pharyngitis
Meningitis x 3 :
N. meningitidis (GpC x 1)
N. meningitidis (untypable x 1)
Pneumonia x 1
(Str. pneumoniae) ?FI
status
Older brother died age 12 of
meningitis
(17)
17 12 F France
Turkish
Parents
from same
village
4 Vi years Pneumonia x 2
Meningitis: H. influenzae type b
Two siblings both well (17)
18 M USA ?
Caucasian
Recurrent sinusitis and pulmonary Urticaria
infections
IgA <6 mg/dl (35-209) some Fi
detected 2.6% (46-159) C3
27 mg/dl (83-177), FB <12 mg/dl
(17-42)
(18)
19 28 F Greek ? 24 years Aseptic meningitis x 11 Sulphonamide allergy Weakly positive ANA 1 :40 to
1 :80
No anti-dsDNA antibodies
(19) I
1
?5
20
21
22
15
18
M Scottish No
Caucasoid
18 months Septic arthritis: 5. epidermidis
Orbital cellulitis, bronchitis
Recurrent otitis media and sinusitis
Cutaneous abscess
Meningitis: N. meningitidis
ANA negative
Asymptomatic
I
3'
43
36 M Swiss No Childhood Recurrent otitis media, sinusitis
bronchopneumonia x 1 0
[Str. pneumoniae
H. influenzae)
Sulphonamide/
penicillin
Allergy one episode
of a multisystem
inflammatory illness
?vasculitic
ANA negative
23 M Spanish Parents
from nearby
villages
3 weeks Cutaneous sepsis (Staph. aureus)
Meningitis x 4: N. meningitidis x 3
Str. pneumoniae x 1
Conjunctivitis
Otitis media, enteritis, septicaemia
Herpes zoster
low lgG2 1.14 g/l (1.30-5.90)
ANA negative
00
Table 1b Reported human C3 deficiency: twenty-two patients from fifteen families (separated by lines) o
Patient Age Sex Nationality Consanguinity Onset of Infections
(years) Race infections
Other complications Notes Reference
1 15 F South Africa Yes
Caucasoid
Infancy Pneumonia x 1 4
Meningitis: N. meningitidis
Otitis media
Erythema gyratum
perstans
Sweet's syndrome
MCGN
Partial C3 gene deletion
No blood neutrophilia during
infection
Normal leucocytosis to infection
Normal Rebuck skin window
(25)
(26)
(27, 28)
(29)
(30)
11 F USA Adopted 1st year Otitis media: H. influenzae bs 
UTI: E. coli
Septicaemia: Str. pneumoniae
South Africa No
Caucasoid
6
7
8
9
10
13
7
5
19
14
F
F
M
F
F
Lebanon
Palestinian
Japan
1 year Meningitis: Str. pneumoniae x 3
Lobar pneumoniae: Str.
pneumoniae
Died age 7 yr 6 mths
Necropsy: purulent meningitis with
polymorphs + + in subarachnoid
space; peripheral lymphoid tissues:
barely discernible germinal centres;
low IgC levels (3.8-6 g/l)
(31)
4
5
3
5
M
F
USA
Caucasoid
USA
Yes
?
-
5 months
No
Pneumonia
Septic arthritis
Otitis media, febrile convulsions
Maculopapular
Arthralgia wrist,
rash
fever
Illness resolved following whole
blood transfusion
Blunted leukocytosis to
infection
(32)
(33)
Frequent earache
Sore throat
bVi years Peritonitis: Str. pneumoniae
3 years Peritonitis
Proteinuria
Microhaematuria
Proteinuria
Microhaematuria
Proteinuria
Left renal artery stenosis
Heterozygous sibling MCCN
(34)
(34)
(34)
I
Yes 'early Bronchitis
childhood'
No
SLE-like symptoms age 16: erythematous rash, fever, (35)
arthralgia, photosensitivity, ANA-ve, LE-ve
SLE-like symptoms age 10: photosensitive facial rash, (35)
arthralgia, ANA-ve, LE-ve
11 10 F Chinese No 8 months Pneumonia
Septic arthritis
Otitis media: H. influenzae
Rash and arthralgia
during infection
Normal leucocytosis during (36)
infection
12 26 F Dutch ? 7 months Meningitis: N. meningitidis Low lgC2 1.48 g/l (3.80± 1.10) (37)
13
14
19
16
Meningitis: Str. pneumoniae
'sepsis': S. aureus
years Meningitis: Str. pneumoniae
Otitis media
8 months Osteomyelitis
Otitis media
Transient
maculopapular rash
during infectious
episodes
Transient
maculopapular rash
during infectious
episodes MCGN
type I
Low lgC2 0.11 g/1 (3.80±1.10)
Low lgC2 0.44 g/l (3.80±1.10)
Administration of FFP of no benefit
(64)
15 M Laos No 5 months Lobar pneumonia
Meningitis: Str. pneumoniae x 2
MCGN Acute administration of FFP not
associated with renal deterioration
(38)
(39)
16 12 Kuwait
Dysfunctional C3 molecules
1 47 F Swedish
2 42 F
No
Nil Microhematuria
Nephrotic syndrome
Renal failure
MCGN Type I
Recurrent otitis media
Meningitis N. meningitidis Gp Y
None SLE
Weak ANA, IgG and IgM at
dermo-epidermal junction
+ ve ANA, anti-dsDNA antibody,
anti-centromere antibody
(40)
17
18
19
20
21
22
6
10
23
14
19
7
M
M
M
F
M
F
Brazil
England
Japan
N. Zealand/
Israel
Yes
Yes
Yes
?
3 months
4
Childhood
Meningitis: N. meningitidis
Bronchopneumonia x 4
Otitis media, osteomyelitis
Otitis media
URTI: Str. pyogenes
Meningitis
Pneumonia
Meningitis: N. meningitidis
x 3
x 2
Transient erythema
multiforme at time of
infection
IgA nephropathy
Lupus-like illness
Normal leucocytosis to infection
First cousin of patient 19
Asthma, rhinitis, otherwise healthy
(41)
(41)
(42)
(42)
(43)
(50)
8
Ir
i
8
I
Table 1c Hereditary Factor H deficiency: twelve patients from six families
Patient Age Sex Nationality Consanguinity Age of Infections
(years) Race onset
Other features Notes Reference
1 8/12 M Indian
M
Yes 8 months Otitis media: H. influenzae
(first cousins)
Haemolytic-uraemic
syndrome (HUS)
Asymptomatic
Very low factor H detected (6% (44)
NHS)
Renal biopsy characteristic of HUS
5 M Algerian Yes 14 months Recurrent otitis and bronchitis
(first cousins) followed by haematuria
Glomerulonephritis
MCGN-like
6/12 M 4 months Otitis media and bronchitis
Septicaemia: E. coli
UTI: Proteus sp.
Persistent haematuria
Glomerulonephritis
MCGN-like
FH 12% NHS in both cases renal
biopsy appearance similar in both:
intramembranous dense deposits
detected atypical
immunofluorescence (IF): anti-C3
staining in mesangium and
capillary walls, not in the basement
membrane H antigen and C5b-9
neoantigens in the areas of C3
staining
(45)
I
2-
EU
Spain No N. meningitidis
N. meningitidis
MCGN
MCGN
MCGN
No factor H antigen detectable in
all sibs
Reduced C5 ( < 1 0 % NHS) and C9
(10% NHS)
No details of renal biopsy given
All ANA negative
(46)
11
Italy Yes None
11 years
Asthma
Haematuria
SLE with nephritis
Anti-dsDNA
antibodies
FH undetectable in all 3 sibs
Heterozygous C2 deficiency
Heterozygous C2 deficiency Renal
biopsy: diffuse proliferative
nephritis 6 of 25 glomeruli with
crescents C3 ( 3 + ) and IgG (1 + )
in mesangium by IF Responded to
prednisolone (2 mg/kg/day)
(47)
10 M Asymptomatic Normal C2
11 15 Danish No 10 years Meningitis x 2:
N. meningitidis Cp B
No detectable FH (48)
Depressed C5 (7% NHS) and C7
( < 0 . 5 % NHS) ?C7 deficiency too
12 49 Netherlands Meningitis: N. meningitidis Gp X SLE/lupus-like illness No details of autoantibodies (49)
Partial factor H deficiency
1 17 M USA ?
Polish
11 years Henoch-Schonlein
purpura
Thrombocytopenia
and splenomegaly
Three other asymptomatic family (51)
members
(52)
F USA ?
Anglo-Irish
63 years ?Recurrent UTIs
38 M
33
26 M
30 years
36 years
26 years
Hypertension
IgA nephropathy
leading to end-stage
renal failure
IgA nephropathy
(mild)
Proteinuria
(52)
Diagnosis on renal biopsy
Renal biopsy performed (sister of
patient 2)
Brother of patient 2
1
I"
IF USA No 18 months Recurrent respiratory tract
infections
Haemolytic-uraemic
syndrome x 3
Died age 2 yrs
Null allele at C4A and C4B
Abnormal C3 variant with reduced
total C3
(53)
OJ
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Table 2 Complement profile of family 1
Mother
Father
Propositus
Sister
Mother
Father
Propositus
Sister
Fl
41
74
-
-
C2
84
96
77
90
All results expressed as
-, undetectable.
FH
96
155
46
42
C3
84
99
28
15
FB
71
71
-
-
C4
71
147
60
105
P
51
52
38
29
C5
137
91
99
48
APH50
50
45
-
-
CH50
92
102
-
-
% normal human serum.
Table 3 Complement profiles of the propositi from family
2 and family 3
Fl FH FB P C4BP APH50 FD100
Propositus 2 - 53 17 34 107 - 82
Propositus 3 - 42 9 38 72 - 68
C2 C3 C4 C5 C7 CH50
Propositus 2 ND 31 159 53 30 47
Propositus 3 ND 31 124 34 36 40
-, undetectable; ND, not determined.
All results expressed as % normal human serum.
patient is now 43 years old and is well apart from
occasional febrile illnesses which respond rapidly to
the administration of antibiotics.
Family 3
A 6-year-old presented with a history of recurrent
pyogenic infections which began at the age of 3
weeks with a cutaneous abscess and omphalitis due
to Staph. aureus. At 3 months, he developed a
second abscess, and at 6 months he started having
persistent folliculitis. When 4 months old, he became
septicaemic with Str. pneumoniae, and at 9 months
he had a further pyrexial illness. At 14, 15 and 16
months of age he had an abscess on the right cheek,
enteritis, and purulent conjunctivitis, respectively.
When 19 months old he suffered a pyrexial illness
with erythematous rash that responded to penicillin.
Four months later, he had two episodes of meningitis
in rapid succession; the first due to N. meningitidis
and the second due to Str. pneumoniae. The follow-
ing month he had otitis media and then septicaemia
with Str. pneumoniae. Between the ages of 3 and 6
years the patient suffered from otitis media, bron-
chitis, enteritis, purulent pharyngitis, and aphthous
stomatitis. When 6 years old, he had an episode of
meningococcal septicaemia after which complement
studies were performed (see Table 2) and the dia-
gnosis of Fl deficiency was made. The immunoglob-
ulin concentrations were: IgG 8.24 g/1 (6.86-14.9);
IgA 1.5 g/l (0.45-3.09); IgM 0.74 g/l (0.41-3.00) and
IgG subtypes were: IgG, 8.07 g/l (3.55-11.25); lgG2
2.67 g/l (1.30-5.90); lgG3 0.26 g/l (0.15-1.05); lgG4
0.26 g/I (0.10-1.10). The concentration of Fl in other
family members is shown in Figure 2. Although the
propositus and his parents now live in Switzerland,
the family was originally from northern Spain, and
the parents of the Fl-deficient boy were from neigh-
bouring villages. There is no history of consanguinity,
however.
The patient was vaccinated with Pneumovax and
II
I l l 107( ) 110 57
IV
Figure 1. The pedigree shows the inheritance of factor I deficiency in the family of Swiss/German origin (family 2). The
propositus is marked with an arrow. The number to the left of the individuals is the factor I concentration in the serum of
that individual expressed as a percentage of the value of normal human serum: normal range 75%—135%.
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Figure 2. The pedigree shows the inheritance of factor I deficiency in the family of Spanish origin (family 3). The propositus
is marked with an arrow. The number to the left of the individuals is the factor I concentration in the serum of that
individual expressed as a percentage of the value of normal human serum: normal range 75%-135%. NT signifies an
individual whose Fl concentration was not tested.
maintained on prophylactic penicillin for 3 years.
During this period he had intermittent bouts of
bronchitis and sinusitis, and when 8 years old,
varicella-zoster. He is now 15, and having withdrawn
prophylactic penicillin of his own volition for 3
years, has remained relatively well with occasional
pyrexial illnesses but no septicaemic episodes.
Methods
Complement assays
Antigenic and functional assays
Serum concentrations of the complement proteins
were assayed by radial immunodiffusion using poly-
clonal antisera (sheep anti-C2, anti-C3, anti-C4,
anti-C5, anti-FI, anti-FH, and anti-properdin: The
Binding Site, Birmingham). Functional complement
assays were performed as follows:20 classical path-
way activity (CH50) was assessed using a haemolytic
assay with sheep red blood cells sensitized with
rabbit antibody (Tissue Culture Services,
Buckingham), in a 1.5% CFD/agarose gel (Oxoid,
Basingstoke); alternative pathway activity (APH50)
was measured by haemolytic assay with guinea pig
erythrocytes (Tissue Culture Services, Buckingham)
in a 1.5% agarose gel in the presence of 7 j iM
MgCI2 and I O U M ethyleneglycol tetraacetic acid
(EGTA). The FD100 is an assessment of factor D (FD)
activity. It was measured in the same way as APH50,
except that the guinea pig erythrocytes were sus-
pended in FD-depleted (by affinity chromatography)
serum. The investigation of the state of circulating
C3 in the Fl-deficient members of family 1 was
carried out by crossed immunoelectrophoresis
according to the method of Laurell, as described in
reference 20.
Assays for cell-bound C3 and CR1
The binding of C3b and its degradation products on
the red cell surface was analysed by radioligand
binding assay as previously described.21 Three
anti-C3 monoclonal antibodies were used (clones 3,
4 and 9, kindly provided by Prof. P. Lachmann,
Cambridge) which recognize C3d, C3c and C3g,
respectively.22 Erythrocyte CR1 numbers were also
measured by radioligand binding assay using the
monoclonal antibody El 1 (kindly provided by Dr
Nancy Hogg, ICRF, London). The binding of this
antibody to the receptor is not affected by the ligation
of CR1 with C3b.23
The purified Fl and FH reagents, used in the ligand
binding studies, were prepared by affinity chromato-
graphy using specific monoclonal antibodies
coupled to cyanogen-bromide-activated Sepharose
(Pharmacia): anti-FI: MRC OX21; anti-FH: MRC
OX23 (Serotec, Oxford).24
Results
Complement estimation
The complement profiles of the four homozygously
affected patients from the three families are given in
Tables 2 and 3. In none of them was Fl detected in
the circulation. The complement profiles of these
patients were similar. They had very low or undetect-
able levels of factor B (FB), and no detectable
alternative pathway activity (APH50). The C3 con-
centrations were also very low. Crossed immuno-
electrophoresis of serum from the two affected sib-
lings from family 1, indicated that 90% of the C3
was in the form of C3b (data not shown). The
reduced concentrations of FH and properdin in all
the propositi to approximately one half of their
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normal value have been documented in all nine
cases of Fl deficiency in which these components
have been assessed.4'9'10'13151719 In one report,15
normal FH and properdin levels were probably the
result of a prior infusion of blood. Reduced levels of
the terminal pathway components C5 and C7 were
found in the affected individuals from families 2 and
3 and the sister of the propositus from family 1 (C5
only). A reduction in C5 has been reported in seven
previous cases,5'910'13'15'17 and a reduction in C7 in
four cases.5'10'17 In none of the reports in which
these two complement components were measured
were normal values recorded.
The results of the radioligand binding studies
performed on family 1 (see Table 4) indicate that the
amount of C3b present on the erythrocyte surface
was increased ten-fold in both homozygotes, as
demonstrated by the binding of the two monoclonal
antibodies to the C3d and C3c portions of C3b. No
increase in binding was observed in the heterozyg-
ously-affected parents. The antibody specific for C3g,
clone 9, recognises a neoantigen on C3 revealed by
the action of Fl. No significant binding was found
with this antibody to erythrocytes from normal or
affected individuals.
Following the incubation of erythrocytes from the
Fl-deficient patient with autologous serum, there was
no change in the pattern of binding observed with
the three different anti-C3 monoclonal antibodies
(see Figure 3). The incubation of the patient's erythro-
cytes with either normal serum, purified Fl, or a
mixture of Fl and FH, resulted in a similar outcome
as regards monoclonal antibody binding: an increase
in clone 9 binding (indicating conversion of C3b to
iC3b and C3dg by Fl); no apparent change in the
binding of clone 3 (which binds to epitopes expressed
in both C3b and in its breakdown products that
remain surface-bound); but a fall in clone 4 binding
(this antibody binds C3c which is cleaved from iC3b
by Fl and released into the fluid phase).
Review of the cases of hereditary Fl, FH and
C3 deficiencies
All the reported cases of hereditary Fl, FH and C3
deficiencies are outlined in Table 1. There are 22
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Figure 3. The treatment of erythrocytes from the propositus
of family 1 with either normal serum or purified factor I
( + /— factor H) resulted in a 2-3 fold increase in the
binding of the monoclonal clone 9 (which binds to
neoepitopes in C3g). The concentration of factor I used
was 10 Hg/ml and the concentration of factor H used was
50 Hg/ml. There was no change in clone 3 binding (which
binds to C3b and its degradation products), and a fall in
clone 4 binding (which binds to the C3c portion of C3).
patients with homozygous C3 deficiency,25"43 23
with Fl deficiency,1"4'7-19 and 12 who lack FH.44^19
Of these, all but one case of homozygous C3
deficiency is symptomatic;43 two cases of Fl16
(family 1, this report) and FH deficiency44'47 are
asymptomatic. In addition, we tabulate one family
in which complete C3 deficiency has resulted from
the inheritance of one null allele and one dysfunc-
tional molecule;50 six instances of partial FH defi-
ciency are also summarized.51"53
Discussion
The most consistent clinical feature of these three
inherited complement deficiencies is susceptibility
to infection. This is predominantly due to pyogenic
organisms and Neisseria meningitidis. Infection with
N. meningitidis was documented in 11/22 cases of
Fl deficiency, in 4/12 cases of FH deficiency, and in
Table 4 Assessment of C3 and CR1 numbers on erythrocytes (family 1)
C3 fragment.. C3d C3c C3g CR1
Monoclonal antibody... (clone 3) (clone 4) (clone 9) (E11)
Mother
Father
Proband
Sister
Normal
"The number of erythrocyte CR1 is subject to a genetic influence, and hence an absolute normal range has limited meaning.
41
74
475
516
45
59
52
573
621
93
15
24
29
27
31
908
645
311
339
300-1300*
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4/22 cases of C3 deficiency. The efficacy of comple-
ment as an opsonin is indicated by the recurrent
pyogenic infections sustained by C3-deficient indi-
viduals. In both Fl and C3 deficiency, defective
opsonization and killing of microbes has been dem-
onstrated with phagocytes from affected individuals
using in vitro assays.4'14'37'39 Moreover, the defective
opsonization and bactericidal activity of leucocytes
were improved, in vitro, if either infusions of FFP
were given,39 or the missing complement component
was replaced, either Fl4 or C3.37
Isolated hereditary deficiency of the terminal path-
way components increases susceptibility to neisserial
infection, implying that the membrane attack com-
plex is important in the eradication of these organ-
isms.54 The increased incidence of neisserial
infections in C3 deficiency is presumably due to the
reduced efficiency of the terminal pathway. Low C5
and C7 levels were found in the propositi from
families 2 and 3 in this paper, confirming observa-
tions from other reports of Fl deficiency.5'9'10'13'15'17
A reduction in the concentration of C5 has been
reported in nine of the ten symptomatic cases of FH
deficiency,45"46 and was normal in only one case.44
In this latter case there was a low level of circulating
FH detected, and no instance of neisserial infection
was recorded in the propositus. C5 is consumed in
FH and Fl deficiency because of the C5 convertase
activity (C3bBbC3b) derived from the alternative
pathway C3 convertase (C3bBbP) which is present
in excess. An additional factor in the predisposition
of these patients to infection may be that opsoniz-
ation of the pathogens by antibody and C3 to form
immune complexes facilitates their delivery to the
splenic macrophage system.55 Therefore, C3-, FH-
and Fl-deficient individuals may be functionally
hyposplenic. The infections typically commence in
early childhood: the median age of the first pyogenic
infection in Fl deficiency was 17 months; in FH
deficiency it was 14 months; and in primary C3
deficiency it was 8 months. Evidence from the three
symptomatic cases presented in this paper suggests
that the frequency of infection declines with age. A
possible explanation of this phenomenon is that as
the immunological memory of the adaptive immune
system expands with increasing age, so the role of
the innate immune system becomes less important.
It is apparent from the data in Table 1 that there
is a marked contrast in the incidence of renal disease
in Fl deficiency compared to the incidence in C3
and FH deficiencies. Clomerulonephritis has not
been described in any of the reported cases of Fl
deficiency, including the four examples reported in
this paper. In C3 and FH deficiencies, there is
frequent evidence of some renal involvement. FH
deficiency seems to have the strongest association
with renal disease. From a total of 12 patients, seven
had definite nephritis: five of these had mesangio-
capillary glomerulonephritis (MCGN),45'46 one had
the haemolytic-uraemic syndrome,44 and another
had crescentic nephritis47 (this patient aJso +iad
heterozygous C2 deficiency). In C3 deficiency, glom-
erulonephritis was recorded in 8/20 patients and in
four of these was of MCGN-type.30-37"39'40 In two of
these cases,37'40 it was specified to be type 1 MCGN,
of which the characteristic feature is subendothelial
deposits. The exact mechanism by which nephritis
develops in these two C3 deficiency states is unclear.
That C3 and FH deficiency patients suffer an MCGN-
like nephritis is interesting because of the association
of this disease with the C3 depletion found in
conjunction with a C3 nephritic factor. The C3
nephritic factor is usually associated with type II
(dense-deposit) MCGN. The association between C3
deficiency and MCGN-like nephritis is further
strengthened by the observation that dogs with
hereditary C3 deficiency develop a nephritis whose
histological pattern is that of MCGN.57
The absence of Fl produces marked abnormalities
of the complement system (see Table 5 for a compar-
ison of the effects of C3, FH and Fl deficiency), and
yet has not been associated with glomerulonephritis.
Thus there is no straightforward relationship between
the derangement of the complement system as meas-
ured in vitro and the predisposition to disease. In Fl
deficiency, only three cases of 'immune complex'
illnesses have been described; one being the multisy-
stem inflammatory disorder that occurred in the
propositus from family 2. Another patient succumbed
to a fatal vasculitic syndrome,15 and the third had a
serum sickness-like syndrome following the adminis-
tration of penicillin.10 The association of immune
complex disease with recurrent infection raises the
possibility that the two are related. Recurrent infec-
tions, by stimulating an acute-phase response, may
theoretically exacerbate an immune-mediated
inflammatory process; alternatively, microbial patho-
gens may act as the antigenic source for immune
complex disease. In one case of FH deficiency,45 in
which there was MCGN-like glomerulonephritis,
recurrent episodes of otitis media and bronchitis
were followed by episodic haematuria. In six patients
with hereditary C3 deficiency, transient maculopapu-
lar skin rashes have developed during infective
episodes.2532-36-37'41 In one study37 circulating
immune complexes (identified by C1q binding assay)
were present at the time when a rash developed in
two patients. Skin biopsy revealed local deposition
of IgG, IgM, C1q, but not C3, by immunofluores-
cence. It is of note that in the three cases of Fl
deficiency in which 'immune complex' type illness
developed (the case from family 2, and those
reported in references 10 and 15) the illness followed
the administration of antibiotic. The complement
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system is also an important effector mechanism in
the inflammatory response. It is therefore possible
that if some residual C3 activity remained the con-
sequences of immune complex deposition/formation
would be aggravated. In one instance of FH defi-
ciency,45 in which there was some FH antigen
detected (12% normal), two siblings both developed
MCGN-like glomerulonephritis. Renal biopsies were
performed and subjected to immunofluorescence.
The results indicated that C3 was deposited in the
mesangium and capillary walls, and that FH and
C5b-9 neoantigens were present in a similar distribu-
tion to C3. The localization of C5b-9 neoantigens
suggests that there was formation of the C5 con-
vertase and that complement was playing an active
part in the inflammatory process.
There may be an increased incidence of nephritis
in cases of partial (heterozygous) complement defi-
ciency. Two families are summarized in Table 1 in
which partial FH deficiency occurs with IgA nephro-
pathy.51-52 There is one instance of IgA nephropathy
in a patient with homozygous C3 deficiency.42 No
disease has been associated with heterozygous Fl
deficiency. In the three families reported, there were
no unusual clinical problems in any of the heterozyg-
ous Fl-deficient individuals. In addition, in one family
in which partial Fl deficiency occurred in conjunc-
tion with C1 -inhibitor deficiency,57 the clinical mani-
festations of the C1-inhibitor deficiency were not
altered by the coexistence of heterozygous Fl defi-
ciency.
A reduced concentration of lgG2 was found in the
propositus from family 3. Low lgG2 concentrations
were found in one family to be associated with
homozygous C3 deficiency37 together with a reduced
antibody response to pneumococcal capsular poly-
saccharide (which is lgG2-dependent).M Antibody
isotypes have not been studied in FH deficiency,
and in family 1, one of the cases of Fl deficiency
reported here, normal concentrations of IgG, and
lgG2 were measured together with a normal lgG2
response to pneumococcal capsular polysaccharide.
In one systematic investigation of IgG subclasses in
complement deficiencies,59 lower mean levels of
lgG2 were found in primary C3 deficiency compared
to normals, and a marked reduction in lgG4 was a
consistent finding in classical pathway and
C3-deficiency states. Using bacteriophage <f>X'\74 as
a test antigen, two C3-deficient patients produced
normal titres of IgM following primary and secondary
immunization, but failed to make an isotype switch
to IgG when the antigen was used at low dose.60 In
C3, Fl, and FH deficiencies, normal antibody
responses to antigens such as tetanus toxoid, dip-
theria, and pertussis vaccine have been recorded.37'48
In one study61 which included one FH-deficient
pedigree in Italy, high titres of antibody against
meningococcal polysaccharides A and C were
observed, presumably as a consequence of natural
infection. However, only a modest response was
then generated by immunization with the meningoc-
occal vaccine, Menpovax A + C.
The mechanism by which five patients (one with-
out C3, and two without FH and Fl) are asymptomatic
is not known. The explanation presumably lies in
the fact that within both the innate and adaptive
immune systems there is a great deal of redundancy.
Thus genetic variation at many loci may influence
the penetrance as well as the expressivity of these
monogenic disorders. The asymptomatic cases of Fl
deficiency were detected because their siblings were
clinically unwell. Because Fl deficiency may be
asymptomatic, it is possible that a substantial propor-
tion of cases are undetected. In one report15 two
cases were identified in two non-consanguinous
families from the Danish island of Funen. The authors
estimate the minimum frequency for the deficient
gene to be 0.002 using the Funen island data.
However, in two large studies, one in 41 083 Swiss
Army recruits,62 and a second in 145 640 blood
donors from Osaka, Japan,63 no instances of C3
deficiency were identified.
The mainstay of treatment at the present time for
these inherited conditions is immunization against
pathogens to which affected individuals are particu-
larly susceptible, Str. pneumoniae, H. influenzae b,
N. meningitidis (vaccination with polysaccharide
antigens types A and C is currently available),
together with the administration of prophylactic anti-
biotics.
An additional potential therapeutic option is
replacement of the deficient complement compon-
ent. Replacement treatment using either fresh-frozen
plasma (FFP) or purified protein has been used in
C337-39,64 a n d F| deficiencies.1'91315 In both circum-
stances, this form of treatment is limited by the high
rate of turnover of the deficient protein. Moreover,
there are two potential drawbacks: firstly, the replace-
ment of a genetically-absent protein may stimulate
an alloimmune response against it; secondly, the
reconstitution of the complement system in the acute
phase may exacerbate the underlying illness. FFP
has been administered in two cases of C3 deficiency
and MCGN with no evidence of improvement or
deterioration in renal function.14"39'64 In one of these
cases a renal biopsy was performed before and after
two months of infusion therapy without evidence of
change in renal function, but there was some histo-
logical improvement, with a reduction of staining for
IgG and C4.64 The nephritis subsequently showed a
definite response to corticosteroid therapy. FFP must
still be used cautiously because of the observation
that in C3-deficient dogs, the nephritis was worsened
by replacement of C3.56
Hereditary complement factor I deficiency 399
The administration of FFP in Fl deficiency has
resulted in a rapid increase in FB and C3 levels.
There was a transient rise in C3d and C4d concentra-
tions, accompanied by a loss of C3 from the patient's
red ceHs together with a slight fall in C4 concentra-
tion.1'9'13'15 No deterioration in clinical condition has
been reported in response to FFP administration,
although in one case anaphylaxis occurred with the
eighth and ninth FFP infusions which were then
halted.15 After an FFP infusion, the decline in the
serum concentration of Fl is paralleled by that of FB.
It has been observed in three instances4'9'15 that
despite the fall in Fl and FB levels there is a
prolonged effect of Fl replacement on the C3 concen-
tration. This starts to decline only after 14 days, at
which time there is no antigenically detectable Fl,
and FB has returned to its baseline level. The
mechanism of this discrepancy is unclear. C2 defi-
ciency has been successfully managed with regular
FFP replacement therapy, and the clinical improve-
ment, in arthralgia and skin rash for instance, has
been observed to last 4 -8 weeks, considerably longer
than the half-life of C2.65
In summary, the four cases of hereditary Fl defi-
ciency described in this paper reflect the range of
clinical manifestations that can occur in this comple-
ment deficiency. The spectrum of illness was from
one individual who was completely asymptomatic,
to another patient who had recurrent pyogenic
infections starting in infancy and continuing until he
was diagnosed at the age of 36 years, together with
a single episode of a multisystem vasculitic illness.
The mechanism by which this variation in disease
expression is generated is not known, but it can not
be accounted for by any differential affects of Fl
deficiency on the complement system that can be
measured in the laboratory. The clinical con-
sequences of primary C3 deficiency and FH defi-
ciency are similar to those of Fl deficiency. There
are some differences, however, notably the predis-
position towards renal disease in C3 and FH defi-
ciency that has not been found in Fl deficiency.
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